USPTO serial 79383070
ZYTOLIGHT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 3, 2024
- Examiner
- BECKER, MARY ELIZABETH
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ZYTOLIGHT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Laurence P. Colton
Laurence P. Colton SMITH TEMPEL BLAHA LLC1600 Parkwood Circle SE, Suite 620Atlanta, GA 30339United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical and veterinary preparations and articles in the nature of medical diagnostic reagents for diagnosis of genetic disorders and genetic aberrations in tumors; diagnostic preparations for medical use; diagnostic preparations for veterinary use; biological preparations for medical purposes, namely, DNA, RNA and oligonucleotide probes, being biochemical reagents, composed of biochemical substances, oligonucleotides, proteins and enzymes and antibodies, all for medical diagnostic purposes, namely, all for the treatment of genetic disorders and genetic aberrations in tumors; biological preparations for veterinary purposes, namely, DNA, RNA and oligonucleotide probes, being biochemical reagents, composed of biochemical substances, oligonucleotides, proteins and enzymes and antibodies, all for veterinary diagnostic purposes, namely, all for the treatment of genetic disorders and genetic aberrations in tumors; chemical preparations for medical purposes, namely, DNA probes, RNA probes and oligonucleotide probes, all being biochemical reagents composed of polynucleotides, biochemical substances, oligonucleotides, proteins and enzymes and antibodies, all for diagnosis of genetic disorders and genetic aberrations in tumors; chemical preparations for veterinary purposes, namely, DNA probes, RNA probes and oligonucleotide probes, all being biochemical reagents composed of polynucleotides, biochemical substances, oligonucleotides, proteins and enzymes and antibodies, all for diagnosis of genetic disorders and genetic aberrations in tumors; diagnostic chemical reagents for medical use; chemical preparations for testing blood for blood disorders, tumor diseases, viruses, bacteria, disease diagnosis and detection, organ function, metabolic disorders, endocrine disorders, hormonal disorders, bacteria-based disorders, virus-based disorders, fungal infections for medical purposes; chemical preparations for use in DNA analysis for medical purposes; chemical reagents for medical or veterinary purposes; diagnostic chemical test reagents for medical purposes; diagnostic chemical test reagents for veterinary purposes; diagnostic agents for pharmaceutical use; diagnostic testing materials in the nature of diagnostic chemical and biological reagents for medical use; indicators for medical diagnosis in the nature of chemical and biological diagnostic reagents; clinical medical reagents; diagnostic reagents for medical use; reagents for use in diagnostic analysis for veterinary purposes; reagents for analytical diagnostic purposes for medical purposes; reagents for analytical diagnostic purposes for veterinary purposes; diagnostic reagents for in-vitro laboratory use for medical purposes; diagnostic reagents for in-vitro laboratory use for veterinary purposes; reagents for use in diagnostic tests for veterinary purposes; diagnostic reagents for microbiological analysis for medical purposes; diagnostic reagents for microbiological analysis for veterinary purposes; reagents for use in diagnostic analysis for medical purposes; reagents for use in diagnostic tests for medical purposes; diagnostic reagents for use with analyzers for veterinary purposes; diagnostic reagents for use with analyzers for medical purposes; reactants for medical diagnosis; reactants for veterinary diagnosis; veterinary diagnostic reagents | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 24, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 6, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 6, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 26, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 8, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 8, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 3, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 3, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 3, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 1, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 1, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 11, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 29, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 29, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 29, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 29, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 29, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 22, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 22, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 22, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 27, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 25, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 25, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 14, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 30, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 21, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 17, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 14, 2023 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Nov 9, 2023 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |